High Dose Carboplatin Reinduction in A Patient With Platinum Refractory and Docetaxel Treated Epithelial Ovarian Cancer

Abstract

Epithelial ovarian cancer is a chemosensitive solid malignancy with overall response rates of 60-80% with platinum-based chemotherapy. ⁽¹⁾ If the cancer fails to respond completely or recurs within 6 months, then a taxane is the most frequently used treatment. It produces overall response rates of up to 50% when used in high doses (200-250 mg/m² of paclitaxel or 100 mg/m2 of docetaxel). ^(2-4) However the response is usually of limited duration. The median progression free and overall survival with taxanes is 6 and 10 to 12 months, respectively. Once patients become resistant to taxanes, the treatment options are limited. We present a case of a patient initially treated with platinum and then docetaxel who on relapse achieved remission with carboplatin reinduction.